December 12, 2024

To all stakeholders,

Perseus Proteomics Inc.
Securities Code: 4882 Growth TSE
email: ir@ppmx.com

# PPMX-T003: Announcement on Extension of Investigator-led Phase I/II Clinical Trial for Aggressive NK-cell Leukemia (ANKL)

Perseus Proteomics Inc. (The Company) hereby announces that the period of investigator-led phase I/II clinical trial of PPMX-T003, an anti-transferrin receptor 1 (TfR1) antibody, for aggressive NK-cell leukemia (ANKL) has been extended until March 31, 2026.

Facing challenges in subject registration due to the target being an exceptionally rare disease, the Company has been preparing for the extension of the clinical trial with the clinical trial coordinators and other related parties. Recently, the clinical trial coordinator determined that it would be difficult to complete the study by March 31, 2025. Thus, an extension of the trial period until March 31, 2026 has been registered with the jRCT (Japan Registry of Clinical Trials), a system for submitting and publicizing clinical research.

The Company is closely examining the impact on the business results of the fiscal year ending March 31, 2025 as well as the following fiscal year and will disclose the results immediately.

END